By Karyn Kaplan and Tracy Swan How can governments and donors effectively address HCV if pharma refuses to drop drug prices? —Paata Sabelashvili, Activist, Georgian Harm Reduction Network Keeping up with the rapid pace of hepatitis C drug development,…
July 2014 By Tracy Swan Thanks to Jules Levin This update includes presentations from the American Association for the Study of Liver Diseases (AASLD) Meeting, the Conference on Retroviruses and Opportunistic Infections (CROI), the European Association for the Study of…
July 2014 By Tracy Swan BONANZA! The Gold Rush Is Under Way The direct-acting antiviral (DAA) era officially began in late 2013, with approval of the first all-oral treatment for hepatitis C virus (HCV) genotypes 2 and 3. A hefty…
July 2015 By Tracy Swan Hepatitis C has to be one of the most grossly miscalculated diseases by governments on the planet. —Michel Kazatchkine, UN secretary general’s special envoy on HIV/AIDS in Eastern Europe and Central Asia and commissioner, Global…
July 15, 2016 By Mark Harrington Due to recent transitions in the TAG HCV Project [1], we did not complete a comprehensive update on hepatitis C virus (HCV) pipeline. Here are a few highlights in HCV regulation, access, and policy…
July 2012 By Karyn Kaplan According to the Universal Declaration of Human Rights and subsequent treaties, all people have a fundamental right to the highest attainable standard of health, as well as a right to the benefits of scientific progress…
December 2012 By Tracy Swan It is difficult to be anything other than dazzled by astounding cure rates of up to 100% from a multitude of interferon-free hepatitis C virus (HCV) clinical trials presented at the American Association for the…
December 2012 Update - Cure rates presented at the American Association for the Study of Liver Diseases (AASLD) July 2012 By Tracy Swan and Karyn Kaplan Dedicated to Michael Carden A fabulous, kind, brilliant, and hilarious friend and colleague 1971–2012…
Fact sheets in English and Spanish covering adherence, hepatitis c diagnostics, hcv genotypes, sofosbuvir/daclatasvir, Mavyret, Solvaldi, Olysio, Vekira XR and Technivie, Harvoni, Daklinza, Zepatier, Epclusa, Ribavirin, and Hepatitis C and the IL28B gene.
TAG and our community partners submitted letters urging the US Delegation to the UN Commission on Narcotic Drugs to express support for draft resolution E/CN.7/2019/L.4.